Last reviewed · How we verify
PF-00592379
At a glance
| Generic name | PF-00592379 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee (PHASE2)
- A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-00592379 CI brief — competitive landscape report
- PF-00592379 updates RSS · CI watch RSS
- Pfizer portfolio CI